Quick Answer
Tango Therapeutics, Inc. reported R&D Expense of $132.16 million for fiscal year 2025.
Tango Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $132.16M | -8.2% |
| 2024 | $143.92M | +24.9% |
| 2023 | $115.20M | +8.8% |
| 2022 | $105.91M | +36.4% |
| 2021 | $77.64M | +55.3% |
| 2020 | $49.99M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $30.82M | -7.4% | -6.1% |
| June 30, 2025 | $32.81M | -15.1% | -10.0% |
| March 31, 2025 | $36.44M | -4.3% | +9.6% |
| September 30, 2024 | $33.26M | +22.5% | -13.9% |
| June 30, 2024 | $38.65M | +34.8% | +1.5% |
| March 31, 2024 | $38.06M | +35.8% | +40.2% |
| September 30, 2023 | $27.15M | -5.5% | -5.3% |
| June 30, 2023 | $28.67M | +20.8% | +2.3% |
- Tango Therapeutics, Inc. showed a decrease of -8.2% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Tango Therapeutics, Inc.’s r&d expense has grown by 164.4% (from $49.99 million to $132.16 million).
- The most recent figure is from Tango Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: